Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 13 | 2020 | 79 | 2.350 |
Why?
|
| Lung | 11 | 2020 | 849 | 1.760 |
Why?
|
| Lung Neoplasms | 5 | 2021 | 1172 | 1.710 |
Why?
|
| Regeneration | 8 | 2013 | 105 | 0.980 |
Why?
|
| Pulmonary Alveoli | 4 | 2017 | 62 | 0.950 |
Why?
|
| Bronchi | 2 | 2020 | 59 | 0.850 |
Why?
|
| Engineering | 1 | 2021 | 7 | 0.810 |
Why?
|
| Fires | 1 | 2020 | 21 | 0.750 |
Why?
|
| Fistula | 1 | 2020 | 29 | 0.740 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 31 | 0.730 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 300 | 0.730 |
Why?
|
| Smoke | 1 | 2020 | 46 | 0.720 |
Why?
|
| Mesothelioma | 1 | 2019 | 21 | 0.710 |
Why?
|
| Blood Vessels | 2 | 2017 | 102 | 0.700 |
Why?
|
| Reperfusion Injury | 2 | 2021 | 320 | 0.700 |
Why?
|
| Bronchial Neoplasms | 1 | 2019 | 12 | 0.690 |
Why?
|
| Plasmacytoma | 1 | 2019 | 15 | 0.680 |
Why?
|
| Airway Resistance | 1 | 2017 | 7 | 0.640 |
Why?
|
| Bronchoscopy | 1 | 2019 | 147 | 0.600 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 439 | 0.570 |
Why?
|
| Neovascularization, Physiologic | 7 | 2013 | 164 | 0.530 |
Why?
|
| Lung Compliance | 2 | 2012 | 10 | 0.510 |
Why?
|
| Green Fluorescent Proteins | 3 | 2013 | 200 | 0.460 |
Why?
|
| Parabiosis | 2 | 2013 | 2 | 0.460 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 189 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 12 | 2013 | 2790 | 0.350 |
Why?
|
| Oxygen | 1 | 2011 | 386 | 0.340 |
Why?
|
| Mice | 14 | 2021 | 8472 | 0.330 |
Why?
|
| T-Lymphocytes | 1 | 2012 | 595 | 0.320 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 799 | 0.310 |
Why?
|
| Animals | 18 | 2021 | 20877 | 0.290 |
Why?
|
| Lung Volume Measurements | 4 | 2013 | 19 | 0.270 |
Why?
|
| Positive-Pressure Respiration | 2 | 2017 | 27 | 0.260 |
Why?
|
| Humans | 11 | 2022 | 68525 | 0.250 |
Why?
|
| Interleukin-15 | 1 | 2022 | 66 | 0.200 |
Why?
|
| Transplants | 1 | 2021 | 28 | 0.200 |
Why?
|
| Lung Injury | 1 | 2021 | 38 | 0.190 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 117 | 0.190 |
Why?
|
| Acrylamides | 1 | 2020 | 12 | 0.190 |
Why?
|
| Neuropilin-2 | 1 | 2020 | 19 | 0.190 |
Why?
|
| Aniline Compounds | 1 | 2020 | 52 | 0.190 |
Why?
|
| Trachea | 1 | 2020 | 48 | 0.180 |
Why?
|
| Lung Transplantation | 1 | 2021 | 88 | 0.180 |
Why?
|
| Disease-Free Survival | 1 | 2020 | 349 | 0.180 |
Why?
|
| Endothelial Cells | 3 | 2011 | 384 | 0.180 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 129 | 0.180 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 265 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 536 | 0.170 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 791 | 0.160 |
Why?
|
| Respiration | 3 | 2013 | 91 | 0.160 |
Why?
|
| Middle Aged | 3 | 2021 | 21119 | 0.160 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 332 | 0.160 |
Why?
|
| Respiratory Mechanics | 1 | 2017 | 33 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2020 | 331 | 0.150 |
Why?
|
| Biopsy | 1 | 2019 | 539 | 0.150 |
Why?
|
| Swine | 1 | 2018 | 672 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 467 | 0.140 |
Why?
|
| X-Ray Microtomography | 2 | 2012 | 50 | 0.140 |
Why?
|
| Cell Proliferation | 3 | 2020 | 1173 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 1139 | 0.130 |
Why?
|
| Stents | 1 | 2020 | 657 | 0.130 |
Why?
|
| Aged | 2 | 2021 | 14842 | 0.130 |
Why?
|
| Organ Size | 2 | 2012 | 242 | 0.130 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1032 | 0.130 |
Why?
|
| Gene Expression Regulation | 4 | 2013 | 1293 | 0.120 |
Why?
|
| Respiratory Paralysis | 1 | 2013 | 10 | 0.120 |
Why?
|
| Phrenic Nerve | 1 | 2013 | 4 | 0.120 |
Why?
|
| Diaphragm | 1 | 2013 | 22 | 0.120 |
Why?
|
| Time Factors | 5 | 2013 | 4655 | 0.120 |
Why?
|
| CD11b Antigen | 1 | 2013 | 47 | 0.110 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2013 | 28 | 0.110 |
Why?
|
| Macrophages, Alveolar | 1 | 2012 | 34 | 0.110 |
Why?
|
| Models, Anatomic | 1 | 2012 | 51 | 0.110 |
Why?
|
| Finite Element Analysis | 1 | 2012 | 55 | 0.110 |
Why?
|
| Thoracic Wall | 1 | 2012 | 20 | 0.110 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1070 | 0.110 |
Why?
|
| Elasticity | 1 | 2012 | 103 | 0.110 |
Why?
|
| Electric Conductivity | 1 | 2012 | 87 | 0.110 |
Why?
|
| Postoperative Period | 1 | 2012 | 238 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.100 |
Why?
|
| Total Lung Capacity | 1 | 2011 | 14 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 75 | 0.100 |
Why?
|
| Tidal Volume | 1 | 2011 | 17 | 0.100 |
Why?
|
| Extraembryonic Membranes | 1 | 2011 | 10 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2019 | 2323 | 0.100 |
Why?
|
| Chick Embryo | 1 | 2011 | 379 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2011 | 190 | 0.090 |
Why?
|
| Stem Cells | 1 | 2011 | 248 | 0.090 |
Why?
|
| Anesthesia | 1 | 2011 | 120 | 0.090 |
Why?
|
| Weight Loss | 1 | 2012 | 319 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2021 | 7028 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2012 | 470 | 0.090 |
Why?
|
| Cell Movement | 3 | 2020 | 630 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2020 | 7264 | 0.080 |
Why?
|
| Female | 3 | 2020 | 38015 | 0.080 |
Why?
|
| Cell Differentiation | 1 | 2011 | 1034 | 0.070 |
Why?
|
| Flow Cytometry | 3 | 2013 | 489 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2012 | 2550 | 0.060 |
Why?
|
| Stereotyped Behavior | 1 | 2004 | 42 | 0.060 |
Why?
|
| Receptors, Dopamine | 1 | 2004 | 119 | 0.060 |
Why?
|
| Neostriatum | 1 | 2004 | 60 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2004 | 68 | 0.060 |
Why?
|
| Healthy Volunteers | 1 | 2022 | 78 | 0.050 |
Why?
|
| Stress, Mechanical | 2 | 2013 | 208 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2022 | 376 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2020 | 57 | 0.050 |
Why?
|
| A549 Cells | 1 | 2020 | 50 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 172 | 0.050 |
Why?
|
| Complement Inactivating Agents | 1 | 2021 | 56 | 0.050 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 562 | 0.050 |
Why?
|
| Proteolysis | 1 | 2020 | 97 | 0.050 |
Why?
|
| Phenotype | 2 | 2013 | 946 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 107 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 369 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2020 | 791 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 331 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2020 | 1199 | 0.040 |
Why?
|
| Corrosion Casting | 1 | 2013 | 2 | 0.030 |
Why?
|
| Synchrotrons | 1 | 2013 | 7 | 0.030 |
Why?
|
| Tomography | 1 | 2013 | 9 | 0.030 |
Why?
|
| Vascular Remodeling | 1 | 2013 | 34 | 0.030 |
Why?
|
| Phosphines | 1 | 2013 | 5 | 0.030 |
Why?
|
| CD18 Antigens | 1 | 2013 | 9 | 0.030 |
Why?
|
| Leukocyte Common Antigens | 1 | 2013 | 41 | 0.030 |
Why?
|
| Blood Cells | 1 | 2013 | 27 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 127 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2012 | 15 | 0.030 |
Why?
|
| Genes, MHC Class II | 1 | 2012 | 29 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 77 | 0.030 |
Why?
|
| Cell Separation | 1 | 2013 | 132 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2013 | 117 | 0.030 |
Why?
|
| Leukocytes | 1 | 2013 | 99 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 24 | 0.030 |
Why?
|
| Cell Count | 1 | 2012 | 248 | 0.030 |
Why?
|
| Pleura | 1 | 2011 | 25 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 29 | 0.030 |
Why?
|
| Transcriptome | 1 | 2013 | 164 | 0.020 |
Why?
|
| Periodicity | 1 | 2011 | 43 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 168 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 218 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 94 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 226 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 312 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 492 | 0.020 |
Why?
|
| Gene Expression | 1 | 2012 | 770 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 498 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1174 | 0.020 |
Why?
|
| Male | 4 | 2013 | 37281 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 705 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 1593 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2011 | 1663 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 1030 | 0.020 |
Why?
|
| Raclopride | 1 | 2004 | 15 | 0.020 |
Why?
|
| Apomorphine | 1 | 2004 | 48 | 0.020 |
Why?
|
| Peromyscus | 1 | 2004 | 14 | 0.020 |
Why?
|
| Quinpirole | 1 | 2004 | 26 | 0.020 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 65 | 0.010 |
Why?
|
| Injections | 1 | 2004 | 119 | 0.010 |
Why?
|
| Benzazepines | 1 | 2004 | 104 | 0.010 |
Why?
|
| Locomotion | 1 | 2004 | 135 | 0.010 |
Why?
|